ABSTRACT: Glucocorticoid-induced osteonecrosis of the femoral head (GIOFH) is a common and devastating orthopedic disease, and its underlying mechanism remains unclear. The aim of this study was to determine the role of microRNA-34a (mir-34a) in GIOFH. C57 mouse mesenchymal stem cells (mMSCs) and human umbilical vein endothelial cells (HUVECs) were cultured with dexamethasone (Dex). A total of 48 adult rats were treated with glucocorticoids, and after the onset of GIOFH, each femoral head was removed. Mir-34a mimics, an inhibitor and over-expressing lentivirus were used in vitro and in vivo, respectively. Real-time PCR, immunohistochemistry, ELISA, cell proliferation assays, osteoblastic differentiation, and endothelial activity assays were employed to evaluate the effect of mir-34a on mMSCs, osteoblasts, and vascular endothelial cells in glucocorticoid-treated mice. We found that Dex inhibited mMSC proliferation and osteoblastic differentiation, as well as the viability and activity of endothelial cells. Dex also caused osteonecrosis and decreased new vessel formation in vivo. Mir-34a alleviated the inhibitory effects of Dex on mMSCs and osteoblasts, while facilitating its inhibitory effects on endothelial cells. Mir-34a is an important regulator in osteogenesis and angiogenesis, and it might be useful as a therapeutic target for GIOFH. ß
Glucocorticoid usage is the most common cause of nontraumatic osteonecrosis of the femoral head (NOFH). 1 As estimated in a recent multi-center investigation, approximately 8 million cases of NOFH have been reported in China; the disorder was caused by glucocorticoids in 26.35% of the male patients and 55.75% of the female patients. Moreover, patients are experiencing glucocorticoid-induced osteonecrosis of the femoral head (GIOFH) at younger ages. 2 Unfortunately, most symptomatic GIOFH patients require surgery, in many cases including total hip replacement (THA). 3 Since, being first reported in the 1950s, the pathogenesis of GIOFH has been extensively studied. Many theories, including the thrombosis theory, 4 the apoptosis theory, 5 suppression of bone formation, 6 and dysregulation between osteogenesis and adipogenesis, 7 jointly form a multifactorial theory of GIOFH, 8, 9 although the precise mechanism remains unclear.
In the past few years, microRNAs (miRNAs) have been shown to perform extensive and crucial regulatory functions in many pathological processes. miRNAs are short (20-24 nT) noncoding RNAs that are involved in the post-transcriptional regulation of gene expression by affecting both the stability and translation of mRNAs. 10 A number of miRNAs, such as mir-17/20a 11 and mir-29a, 12 have been recognized as playing a functional role in glucocorticoid-induced bone loss as well as necrosis. In a recent study, we determined which miRNAs are abnormal in patients with GIOFH and femoral neck fractures using miRNA microarray assays, and the results showed significant upregulation of the expression of 12 miRNAs (including mir-34a), while 5 other miRNAs were down-regulated. 13 Based on previous studies, we know that mir-34a possesses many functions, mainly acting within various types of tumors. Kumar et al. reported that mir-34a inhibits tumor angiogenesis via down-regulating VEGF secretion in head and neck squamous cell carcinoma.
14 Tian et al., 15 and Yamakuchi et al. 16 revealed that silent information regulation factor 1 (SIRT1) is one of the targets of mir-34a. Through SIRT1, mir-34a reciprocally interacts with p53, which regulates cell apoptosis in human osteosarcoma. In addition, mir-34a participates in inhibiting osteoblastic differentiation in human stromal stem cells. 17 Additionally, Kang et al. showed that mir-34a-5p is a key regulator in the impairment of the formation of bone marrow stromal stem cells by glucocorticoids. 18 These functions are closely related to the mechanisms of GIOFH and, combined with the fact that the expression of mir-34a was significantly increased in GIOFH patients, stimulated our interest in determining how mir-34a participates in the process of GIOFH.
In this study, we investigated the role of mir-34a in GIOFH in angiogenesis and osteogenesis, both in vitro and in vivo, to provide a new and promising target for early treatment.
MATERIALS AND METHODS
Cell Culture C57BL/6 mouse mMSCs and human umbilical vein endothelial cells (HUVECs) were purchased from KeyGEN Biotech Inc. (Shanghai, China). Identification of the mMSCs and HUVECs was performed by the provider. All C57BL/6 MSC cell lines were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco, MA), and the HUVEC cell lines were cultured in RPMI-1640 (Gibco) medium; both media contained 10% FBS and 100 mg/ml penicillin/streptomycin. The cells were cultured at 37˚C in an incubator supplemented with 5% CO 2 . Osteoblastic differentiation was performed by osteoblast-induced medium (Cyagen, CA) containing basic medium with 50 mg/ ml ascorbic acid, 10 À8 M dexamethasone (Dex), and 10 mM b-glycerophosphate. Different concentrations of Dex (10 À6 , 10 À7 , and 10 À8 M) were used to estimate the dose effects on the cell proliferation and differentiation of mMSCs and HUVECs; the expression of mir-34a was also evaluated. Then, mir-34a mimics and an inhibitor (GenePharma, Shanghai, China) were used to evaluate the effect of mir-34a during culture.
Cell Proliferation Assay
A cell counting kit (CCK-8) assay (KeyGEN Biotech Inc, Shanghai, China) was performed to measure the cell proliferation rate. Cells were seeded onto 96-well plates at a density of 5 Â 10 4 cells/ml. After incubation for 24 h, 10 ml of reagent was added to each well, and all cells were incubated for another 2 h. The optical density (OD) value at a wavelength of 450 nm was measured. The absorbance at OD 450 was used to evaluate the cell proliferation rate. The OD value of each well was measured three times.
Alkaline Phosphatase (ALP) and Alizarin Red (ALR) Staining mMSCs were seeded onto 24-well plates at a density of 1 Â 10 5 cells/ml. Osteoblast-induced medium was applied for 2 weeks, and then all mMSCs were subjected to ALP and ALR staining according to the manufacturer's protocol. Briefly, the cells were washed twice with phosphate buffered saline (PBS), fixed with 70% alcohol for 1 h, and then stained with ALP or ALR solution (KeyGEN Biotech Inc) for 3 h. Before being photographed, each well was washed with double distilled water three times. All staining reactions were repeated three times.
Scratch and Tube Formation Assay
HUVECs were seeded onto 6-well plates at a density of 5 Â 10 5 cells/ml and cultured for nearly 24 h until they reached 80% confluence. Pipette tips were used to make vertical grooves in the middle of the well. The migration of endothelial cells was observed using a microscope at 0, 6, 12, and 24 h following inoculation. Matrigel purchased from Corning Inc., NY, was used to perform the endothelial cell tube formation assay, and all procedures were conducted according to Arnaoutova's report. 19 In brief, Matrigel was thawed at 4˚C in ice, and all plates and tips were stored at À20˚C overnight. The bottom of each well was evenly coated with 200 ml of Matrigel, and the plate was immediately placed into an incubator for 1 h before the cells were seeded. Tube formation of the cells was monitored using a microscope 6 h after inoculation.
ELISA
HUVECs were cultured in 24-well plates until reaching 80% confluence. Then, the cells were washed, and fresh medium was added. After 24 h, the supernatant was collected, and VEGF levels were measured using a human VEGF ELISA kit (Multisciences, Hangzhou, China) per the manufacturer's instructions. All measures were repeated three times.
In Vivo Experiments With Rats
The 48 male adult rats were randomly distributed into three groups (12 in the control group, 24 in the Dex group, and 12 in the mir-34a over-expression lentivirus group). The rats in the Dex group were given two injections of lipopolysaccharide (LPS, 20 mg/kg, Sigma, MO) at an interval of 24 h, and then dexamethasone (40 mg/kg, Pfizer, NY) was injected into the gluteus muscle daily for 3 days, as described in a previous study. 20 The animals in the lentivirus group received an extra intravenous injection of mir-34a over-expressing lentivirus at a dose of 1E þ 8 TU (Genechem Co. Ltd, Shanghai, China) 1 day before LPS injection. The rats in the control group were treated with intramuscular saline in the same amounts as the active treatments in the other groups. Twelve rats from the Dex group were euthanized on the 4th week, while the others were euthanized on the 8th week by cervical dislocation. Every femoral head was removed and fixed in 10% neutral buffered formalin or stored in a À80˚C freezer for H&E staining, immunohistochemistry, and PCR.
Quantitative Real-Time PCR RNA was extracted from the mMSCs, HUVECs and the rats' femoral heads using TRIzol reagent (Invitrogen, CA) according to the manufacturer's instructions. For reverse transcription, the synthesis of first complementary DNA (cDNA) was performed using PrimeScript RT reagent kits (Takara 027, Shiga, Japan). Real-time PCR was performed using a SYBR GREEN qRT-PCR kit (Takara 480, Shiga, Japan). U6 was used as the reference for mir-34a, while GAPDH was used for the other mRNAs. The sequences of mir-34a and other mRNAs used were as follows: Mir-34a RT:
Compliance With Ethical Standards
All animals were kept in a standard environment and provided sufficient water and food. All procedures involving mice were approved by the Shanghai Fudan University Animal Study Committee and were performed in accordance with the guide for the humane use and care of laboratory animals.
Statistical Analysis
All data are expressed as the mean AE SEM. Statistical analysis was performed using one-way ANOVA. Values were considered to be significantly different at p < 0.05. All statistical analysis was performed using SPSS 13.0 software.
RESULTS

Regulatory Effect of mir-34a on Dex-Inhibited mMSC Proliferation
First, we investigated the effect of Dex on mMSC proliferation. Different concentrations of Dex (0, 10 À6 , 10
À7
, and 10 À8 M) were administered to the mMSC cultures, and cell proliferation rates were tested on days 1, 3, 5, and 7. The expression of mir-34a in the mMSCs was measured on day 7. The results showed that Dex inhibited mMSC proliferation and mir-34a expression, and this effect was promoted by increases in concentration and the time of exposure (Fig. 1a and  b) . Then, the over-expression and inhibition of mir-34a were induced using mir-34a mimics and an inhibitor (Sangon Biotech, Shanghai, China) to evaluate the function of mir-34a. We found that the inhibitory effect of Dex on mMSC viability could be alleviated by mir-34a mimics, while a decrease in mir-34a expression enhanced the reduction of mMSC proliferation (Fig. 1c) .
Regulatory Effect of mir-34a on Dex-Inhibited mMSC Osteoblastic Differentiation
To explore the role of mir-34a in Dex-decreased mMSC osteoblastic differentiation, mir-34a mimics and an inhibitor were transfected into mMSCs. After the cells were induced to osteoblasts for 2 weeks, ALP and ALR staining was performed. The results clearly showed that Dex inhibited the osteogenesis process; the transfection of mir-34a mimics alleviated this effect of Dex, while the mir-34a inhibitor aggravated it (Fig. 2a) . The qRT-PCR results revealed that the expression of Runx2 and Osterix, which are vital factors in osteoblastic differentiation, was negatively regulated by Dex levels (Fig. 2b) . mir-34a mimics alleviate the inhibitory effect of Dex on the expression of Runx2 and Osterix, while À7 , and 10 À8 M Dex for 7 days, then the CCK-8 assay showed that Dex decreased mMSC viability in a time-and dose-dependent manner. (b) qRT-PCR results showed that mir-34a expression in mMSCs was inhibited by Dex in a dose-dependent manner. (c) The mir-34a mimics and the inhibitor were transfected into mMSCs, and the cell proliferation rate was tested at days 1, 3, 5, and 7.
ÃÃ p < 0.05.
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the mir-34a inhibitor strongly decreased the expression of these factors ( Fig. 2c and d) .
Next, we used a mir-34a over-expressing lentivirus in the rat model to investigate whether mir-34a serves the same function in vivo. The over-expression lentivirus was injected into the tail vein, and after 24 h, two random animals in the lentivirus group were sacrificed to detect the transfection of lentivirus. The qRT-PCR results showed a significant increase in mir-34a expression in the samples (Fig. 2g) , which demonstrated the successful transfection of mir-34a lentivirus. H&E staining exhibited abundant empty osteo-lacunae and empty cartilage lacunae in the Dex group, while few empty lacunae were found in the lentivirus group (Fig. 2h) . Compared with the control group, Runx and Osterix mRNA expression in the femoral head samples significantly decreased in the Dex group, while the expression levels in the mir-34a lentivirus group increased to the normal level ( Fig. 2i and j) . ÃÃ p < 0.05 (e) mir-34a lentivirus was injected into rats through the tail veins and after 24 h, two animals were chosen at random and sacrificed, and the femoral bone samples were used to evaluate the transfection by qRT-PCR.
ÃÃ p < 0.01 (f) H&E staining was performed to evaluate the effect of mir-34a on osteoblastic differentiation in vivo. Many empty osteo-lucanae (blue arrow) and empty cartilage lacunae (red arrow) were found in the Dex group, while few were scanned in the lentivirus goup. Scale bars are 20 mm. (g,h) Runx2 and Osterix mRNA expression in the femoral head was tested by qRT-PCR.
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Effect of mir-34a on Dex-Decreased HUVEC Viability and Activity
We studied the effect of Dex on HUVECs. The HUVECs were cultured with 0, 10
À6
, 10
À7
, and 10 À8 M Dex, and cell proliferation was tested by the CCK-8 assay on days 1, 3, 5 and 7. mir-34a expression in the cells and the VEGF protein levels in the supernatant were measured on day 7. The results showed that Dex inhibited HUVEC viability and VEGF secretion in a dose-and time-dependent manner, while mir-34a expression in HUVECs was increased by Dex (Fig. 3a-c) . Next, we applied mir-34a mimics and an inhibitor to adjust the mir-34a level. The transfection of mir-34a mimics markedly facilitated the Dexinhibited viability of HUVECs, while the inhibitor alleviated it (Fig. 3d) .
We used a scratch and tube formation assay to assess the endothelial cells' activity. The results were similar to the viability results. The migration movements were inhibited by Dex and further decreased by the transfection of mir-34a mimics (Fig. 3e) . Few tubes were found in cells treated with Dex compared to the cells without Dex; however, with the transfection of the mir-34a inhibitor, the tube-forming ability was improved (Fig. 3f) . In addition, the protein level in the supernatant indicated that the secretion of VEGF was up-regulated by the mir-34a inhibitor and downregulated by the mir-34a mimics (Fig. 3g) .
In vivo, CD31 immunohistochemistry was used to evaluate new vessel formation. We found few new vessels in the Dex group compared with the control group at the end of the 4th week. However, on the 8th week, many new vessels were scanned in the proximal cavum medullare adjacent to the necrotic area in the Dex group, while few were observed in the mir-34a lentivirus group (Fig. 3h) .
DISCUSSION
Dysregulations of osteogenesis and angiogenesis are two important pathways in glucocorticoid-induced necrosis of the femoral head. Although many previous studies have shown that Dex can inhibit the formation of new bone and vessels under various conditions, the molecular mechanisms remain unclear. 21, 22 In this study, we identified that mir-34a is a key regulator in both processes and that it plays different roles in each process.
In recent years, some miRNAs have been shown to play vital roles in bone biology. 23 Guo et al. reported that the up-regulation of mir-17-92a by estrogen leads to the inhibition of osteoblast apoptosis; additionally, Bim protein was further identified as a target of mir-17-92a in this process. 24 Ko et al. reported that mir-29a improved Dex-inhibited osteoblastic differentiation by enhancing the deacetylation of b-catenin. 12 Shi et al. demonstrated that glucocorticoids inhibit cell proliferation in differentiating osteoblasts by mir-199a targeting of Wnt signaling. 25 In addition, the mir-34 family was reported to be a regulator of murine osteoblasts and the function of mir-34b/c, not mir-34a, was detected in mouse osteoblasts. 26 In our previous study, we found that mir-34a was significantly upregulated in the bone samples from GIOFH patients compared with the control groups, and no reports have previously been made regarding the function of mir-34a in GIOFH. The present study determined the role of mir-34a in GIOFH.
There are two conflicting opinions about the effect of mir-34a in osteoblasts. Li et al. reported that mir-34a inhibits osteoblast differentiation and in vivo bone formation of human stromal stem cells, 17 while Deng et al. claimed that mir-34a-5p is reciprocally regulated by Dex and improves osteoblast differentiation. 18 In our findings, we verified the achievements of Deng, and we were the first to construct a mir-34a over-expressing lentivirus and transfect it into rats. The in vivo results were consistent with the in vitro results, especially the expression of Runx2. Runx2 was shown to be a key modulator of osteoblast formation, and many hormones and cytokines are involved in the regulation of Runx2. 27, 28 In our study, we found that Runx2 participates in Dex-inhibited osteogenesis; furthermore, Runx2 is a target of mir-34a to regulate osteoblastic differentiation.
The current study also provides an explanation for why mir-34a was up-regulated in the bone samples of necrotic femoral heads in Yuan's study. 13 In this study, the samples used for analysis were derived from reparative regions that consist of disordered and thickened newly formed osteocytes, 29 not the necrotic areas.
The effect of Dex on endothelial cells has already been discussed. Some investigators propose that Dex directly injures endothelial cells, leading to the release and aggregation of vasoactive substances, which cause hypercoagulation and thrombosis. 30, 31 Other researchers suggest that another consequence is the decrease in endothelial viability and activity, which finally affects vascularization and blood supply. 32 The functions of numerous miRNAs in angiogenesis have been recognized over the past few years. mir-34a was found to be involved in various types of tumor angiogenesis and cell migration, 14, 33, 34 and it has been shown that mir-34a is expressed in endothelial cells. 35 Feng et al. reported that mir-34a mimics caused increased DNA doublestrand breaks (DSBs), while a mir-34a inhibitor caused decreased DSBs of HUVECs under the condition of tritiated water, likely by regulating c-myc expression. 36 All of these studies together reveal that mir-34a functions as a down-regulator in endothelial proliferation and angiogenesis under different conditions, although no studies have investigated the function of mir-34a in glucocorticoid-inhibited angiogenesis.
Our data showed that HUVEC proliferation, migration and tube formation ability were all inhibited by Dex; the over-expression of mir-34a facilitated this Dex effect, and the inhibition of mir-34a reversed it. In vivo, the situation was more complicated because rats ROLE OF Mir-34a IN OSTEONECROSIS 
À7
, and 10 À8 M Dex for 7 days, then CCK-8 assays were applied to test the cell proliferation rate. ÃÃ p < 0.05 (b,c) mir-34a mRNA expression of cells and VEGF protein levels in the supernatant were measured by qRT-PCR.
ÃÃ p < 0.05 (d) HUVECs cultured with Dex were transfected with mir-34a mimics and an inhibitor for 7 days, and the cell proliferation rates were measured by the CCK-8 assay. ÃÃ p < 0.05. (e) HUVECs were seeded onto 6-well plates; a scratch test was used, and the migration rates were observed at 0, 6, 12, and 24 h to evaluate the migration ability of the endothelial cells. Scale bars are 100 mm. (f) HUVECs were seeded onto 12-well plates before Matrigel was applied. After 6 h, tube formation ability was evaluated. Scale bars are 100 mm. (g) HUVECs cultured with Dex were transfected with mir-34a mimics and an inhibitor for 7 days, and VEGF protein levels were measured by ELISA .
ÃÃ p < 0.05. (h) CD31 expression and localization in the proximal cavum medullare adjacent to the necrotic area around new vessels (black arrow). Scale bars are 100 mm.
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ZHA ET AL. are quadrupedal. There was minimal new vessel growth in the Dex group at the 4th week, but many new vessels formed by the 8th week. We do not consider these phenomena to be paradoxical. New vessel formation was at first inhibited by Dex, then this effect was gradually weakened, and the reparative process started, which led to higher numbers of new vessels in the Dex group at the 8th week. Meanwhile, few new vessels were detected in the mir-34a lentivirus group on the 8th week, implying decreased vascular recovery. We suggest that the transfection of a mir-34a over-expressing lentivirus led to a direct and acute inhibitory effect on angiogenesis in the early stage of GIOFH, but it disturbed the normal vascular reparative process in the compensatory phase, which then indirectly aggravated GIOFH. This report is the first study investigating the effects of mir-34a on HUVECs under the condition of glucocorticoids, and in live GIOFH animal models, we found that mir-34a plays a negative regulatory role in angiogenesis.
VEGF is a crucial factor in angiogenesis that regulates endothelial cell proliferation, migration, and vascularization. 37, 38 Previous studies have revealed that Dex can decrease VEGF expression in osteoblasts, 39 and our study focused on the VEGF expressed by endothelial cells because we suggest that the direct endothelial damage caused by Dex leads to reductions in VEGF, which affects angiogenesis. Zhang et al. found that the over-expression of mir-34a has no effect on VEGF mRNA expression, but ELISA showed a significant decrease in VEGF protein in LV-mir-34a. 40 We also found that VEGF expressed by HUVECs was inhibited by Dex, and the transfection of mir-34a down-regulated it at the protein level, which indicates that VEGF might be a regulatory target of mir-34a in Dex-inhibited angiogenesis.
In conclusion, our study identified that mir-34a is a key regulator in both Dex-inhibited osteogenesis and Dex-inhibited angiogenesis. mir-34a is regulated by Dex and functions as a positive regulator in mMSC proliferation and osteoblastic differentiation, while it functions as a negative regulator in HUVEC proliferation and angiogenesis. Our study demonstrates a molecular mechanism of GIOFH and provides a miRNA target for further investigation.
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